

## Optum Specialty Phone: 855-427-4682 Optum Specialty Fax: 877-342-4596

## Osteoporosis Enrollment Form

Specialty Pharmacy Enrollment Form

 $\ensuremath{\text{@}}\xspace$  Please detach before submitting to a pharmacy – tear here.

This form is not a valid prescription in Arizona or Virginia

| PATIENT INFORMATION   |                                    |  | PRESCRIBER INFORMATION                                      |     |        |         |
|---|------------------------------------|--|---|-----|--------|---------|
| Please complete the following or <b>send patient demographic sheet</b> Patient Name   |                                    |  | Prescriber's Name DEA                                       |     |        |         |
| Address   |                                    |  | NPI   |     |        |         |
| Address 2   |                                    |  | Group/Hospital  |     |        |         |
| Home Phone Alternate Phone  |                                    |  | City, State, ZIP  |     |        |         |
| DOB Last Four of SS# Gender   |                                    |  | Phone Fax   |     |        |         |
| Language Preference: English Spanish Other  |                                    |  | Contact Person  |     |        |         |
|   | al to a leading a leader at also a |  |   |     |        |         |
| INSURANCE INFORMATION (Must fax a copy of patient's insurance card including both sides)  Prior Authorization Reference number  |                                    |  |   |     |        |         |
| MEDICAL INFORMATION (Section must be completed to process prescription) (Attach separate sheet if needed)   |                                    |  |   |     |        |         |
| Diagnosis — Please include diagnosis name with ICD-10 code  |                                    |  | Additional Information Therapy: New Reauthorization Restart |     |        |         |
| Description   |                                    |  | Weightkg/lbs Heightcm/in BSAm²                              |     |        |         |
| Disease State Description:  |                                    |  | Allergies   |     |        |         |
| Postmenopausal osteoporosis with high fracture risk (female)  |                                    |  | Fracture History  |     |        |         |
| Postmenopausal osteoporosis prophylaxis   |                                    |  |   |     |        |         |
| Hypogonadal osteoporosis with high fracture risk (male)   |                                    |  | Prior Failed Therapies:                                     |     |        |         |
| Glucocorticoid-induced osteoporosis treatment/prophylaxis   |                                    |  | Actonel® (risedronate) Boniva® (ibandronate)                |     |        |         |
| Paget's disease   |                                    |  | Fosamax® (alendronate) Prolia® (denosumab)                  |     |        |         |
| Other:  |                                    |  | Reclast® (Zoledronic Acid Injection)                        |     |        |         |
| Date of Diagnosis   |                                    |  | Concomitant Medications                                     |     |        |         |
| Test Results: WNL:  |                                    |  |   |     |        |         |
| Serum calcium Yes No  |                                    |  | Additional Comments   |     |        |         |
| SCr/CrCl Yes No   |                                    |  |   |     |        |         |
| ☐ BMD Yes ☐ No  |                                    |  | Treatment Start Date Treatment End Date                     |     |        |         |
| T score Yes   |                                    |  |   |     |        |         |
| PRESCRIPTION INFORMATION  |                                    |  |   |     |        |         |
| Medication  | Dose/Strength                      |  | Directions  | Qua | intity | Refills |
| Forteo®   |                                    |  |   |     |        |         |
| ☐ Prolia®   |                                    |  |   |     |        |         |
| Reclast®  |                                    |  |   |     |        |         |
| ☐ Tymlos®   |                                    |  |   |     |        |         |
|   |                                    |  |   |     |        |         |
| *Prescriber Authorization: I authorize this pharmacy and its representatives to act as my authorized agent to secure coverage and initiate the insurance prior authorization process for my patient(s), and to sign any necessary forms on my behalf as my authorized agent, including the receipt of any required prior authorization forms and the receipt and submission of patient lab values and other patient data. In the event that this pharmacy determines that it is unable to fulfill this prescription, I further authorize this pharmacy to forward this information and any related materials related to coverage of the product to another pharmacy of the patient's choice or in the patient's insurer's provider network. |                                    |  |   |     |        |         |
| Ship to: Patient Office Other Date Needs by Date  |                                    |  |   |     |        |         |
| Product Substitution permitted Dispense as Written Supervising  |                                    |  |   |     |        |         |
| Prescriber's Signature Date   |                                    |  | hysician ignature: Date                                     |     |        |         |
| Electronic or digital signatures not accepted.  | Date                               |  |   |     | Date   |         |
| CONFIDENTIALITY STATEMENT: This communication is intended for the use of the individual or entity to which it is addressed and may contain information that is privileged, confidential, and exempt from disclosure under applicable law. If the reader of  |                                    |  |   |     |        |         |

CONFIDENTIALITY STATEMENT. This communication is intended for the use of the individual or entity to which it is addressed and may contain information that is privileged, confidential, and exempt from disclosure under applicable law if the reader of this communication is not the intended recipient or the employee or agent responsible for delivery of the communication, you are hereby notified that any dissemination, distribution, or copying of the communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone. This form is not a valid prescription in Arizona or Virginia.